Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,608 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer.
Sekine I, Nokihara H, Takeda K, Nishiwaki Y, Nakagawa K, Isobe H, Mori K, Matsui K, Saijo N, Tamura T. Sekine I, et al. Among authors: mori k. Br J Cancer. 2008 Feb 26;98(4):693-6. doi: 10.1038/sj.bjc.6604233. Epub 2008 Feb 5. Br J Cancer. 2008. PMID: 18253118 Free PMC article. Clinical Trial.
Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI).
Sekine I, Nishiwaki Y, Noda K, Kudoh S, Fukuoka M, Mori K, Negoro S, Yokoyama A, Matsui K, Ohsaki Y, Nakano T, Saijo N; Japan Clinical Oncology Group (JCOG) Lung Cancer Study Group. Sekine I, et al. Among authors: mori k. Ann Oncol. 2003 May;14(5):709-14. doi: 10.1093/annonc/mdg213. Ann Oncol. 2003. PMID: 12702524 Free article. Clinical Trial.
Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer.
Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, Masutani M, Nakata K, Tsuchiya S, Isobe H, Saijo N. Okamoto H, et al. Among authors: mori k. J Clin Oncol. 1999 Nov;17(11):3540-5. doi: 10.1200/JCO.1999.17.11.3540. J Clin Oncol. 1999. PMID: 10550152 Clinical Trial.
Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601).
Tsuchiya S, Ohe Y, Sugiura T, Fuwa N, Kitamoto Y, Mori K, Kobayashi H, Nakata K, Sawa T, Hirai K, Etoh T, Saka H, Saito A, Fukuda H, Ishizuka N, Saijo N; Japan Clinical Oncology Group Study. Tsuchiya S, et al. Among authors: mori k. Jpn J Clin Oncol. 2001 Oct;31(10):488-94. doi: 10.1093/jjco/hye106. Jpn J Clin Oncol. 2001. PMID: 11696618 Clinical Trial.
Phase I/II trial of a biweekly combination of S-1 plus docetaxel in patients with previously treated non-small cell lung cancer (KRSG-0601).
Komiyama K, Kobayashi K, Minezaki S, Kotajima F, Sutani A, Kasai T, Mori K, Hoshi E, Takayanagi N, Koyama S, Eguchi K, Nakayama M, Kikuchi K; Kanto Respiratory Disease Study Group. Komiyama K, et al. Among authors: mori k. Br J Cancer. 2012 Oct 23;107(9):1474-80. doi: 10.1038/bjc.2012.437. Epub 2012 Oct 2. Br J Cancer. 2012. PMID: 23033004 Free PMC article. Clinical Trial.
7,608 results